Does simvastatin stimulate bone formation in vivo? by von Stechow, Dietrich et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Musculoskeletal Disorders
Open Access Research article
Does simvastatin stimulate bone formation in vivo?
Dietrich von Stechow1, Susan Fish2, Dror Yahalom2, Itai Bab2,3, 
Michael Chorev2, Ralph Müller4 and Joseph M Alexander*2
Address: 1Orthopedic Biomechanics Laboratory, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA, 2Bone and 
Mineral Metabolism Unit, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA, 3Bone Laboratory, Institute for 
Dental Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel and 4Institute for Biomedical Engineering, ETH and University Zürich, 
Switzerland
Email: Dietrich von Stechow - dvonstec@caregroup.harvard.edu; Susan Fish - Sfish@Wyeth.com; 
Dror Yahalom - dyahalo@caregroup.harvard.edu; Itai Bab - babi@cc.huji.ac.il; Michael Chorev - mchorev@caregroup.harvard.edu; 
Ralph Müller - Ralph.Mueller@biomed.ee.ethz.ch; Joseph M Alexander* - jalexand@caregroup.harvard.edu
* Corresponding author    
Abstract
Background: Statins, potent compounds that inhibit cholesterol synthesis in the liver have been
reported to induce bone formation, both in tissue culture and in rats and mice. To re-examine
potential anabolic effects of statins on bone formation, we compared the activity of simvastatin
(SVS) to the known anabolic effects of PTH in an established model of ovariectomized (OVX)
Swiss-Webster mice.
Methods: Mice were ovariectomized at 12 weeks of age (T0), remained untreated for 5 weeks to
allow development of osteopenia (T5), followed by treatment for 8 weeks (T13). Whole,
trabecular and cortical femoral bone was analyzed by micro-computed tomography (micro CT).
Liquid chromatography/mass spectrometry (LC/MS) was used to detect the presence of SVS and
its active metabolite, simvastatin β-hydroxy acid (SVS-OH) in the mouse serum.
Results: Trabecular BV/TV at T13 was 4.2 fold higher in animals treated with PTH (80 micro-g/kg/
day) compared to the OVX-vehicle treated group (p < 0.001). However, the same comparison for
the SVS-treated group (10 mg/kg/day administered by gavage) showed no significant difference (p
= NS). LC/MS detected SVS and SVS-OH in mouse serum 20 minutes after gavage of 100 mg SVS.
A serum osteocalcin assay (OC) demonstrated that neither bone formation nor osteoblast activity
is significantly enhanced by SVS treatment in this in vivo study.
Conclusions: While PTH demonstrated the expected anabolic effect on bone, SVS failed to
stimulate bone formation, despite our verification by LC/MS of the active SVS-OH metabolite in
mouse serum. While statins have clear effects on bone formation in vitro, the formulation of existing
'liver-targeted' statins requires further refinement for efficacy in vivo.
Background
Statins, potent compounds that inhibit cholesterol syn-
thesis in the liver by blocking 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA), have been reported to induce
osteoblast activity and lead to bone formation, both in tis-
sue culture and in rats and mice [1–6]. These findings, if
confirmed and extended to include humans, have the po-
tential to introduce immediate new treatment options to
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patients with low bone mass and osteoporosis. Such treat-
ment is readily available, since an estimated 3 million pa-
tients in the US alone take statins daily to treat
hyperlipidemia with few side effects [7]. Osteoporosis is
increasingly recognized as an eminent public health prob-
lem, as the mean age of populations in most Western
countries increases and costs related to osteoporosis are
expected to grow six-fold by the year 2040 [8]. Data from
the National Health and Nutrition Examination Survey,
using a definition of osteoporosis developed by the World
Health Organization, estimate that in the United States up
to 20% of Caucasian women over 50 have osteoporosis
and up to 50% have low bone mass. Non-caucasian wom-
en and men tend to have lower rates of osteoporosis but
contribute up to 25% of the fractures annually [9].
The only bone anabolic agent known to increase bone
mineral density in both animal models and clinical set-
tings is human parathyroid hormone 1–34 (PTH), which
has recently been approved by the FDA in patients with
advance osteoporosis [10]. Bone-related basic and clinical
research has been searching intensively for alternative an-
abolic agents for the treatment of osteoporosis.
Due to the potential clinical impact of statins as a treat-
ment option for patients with low bone mass and oste-
oporosis, it is essential to evaluate its anabolic activity in
several in vitro and experimental animal models. We have
recently reported the anabolic action of PTH in an ovariec-
tomized (OVX) Swiss-Webster mouse model, which like
the rat model, displays a substantial amount of trabecular
bone in its femoral metaphyses and a quantifiable loss of
bone following OVX [11]. The aim of this study was to in-
vestigate the effect of simvastatin on the microarchitecture
of bone in an established mouse model of osteoporosis,
and compare its anabolic action with PTH. We also veri-
fied the presence of systemically administered simvastatin
in the mouse serum, as this has previously not been re-
ported and is likely to be of critical importance when eval-
uating the effect of simvastatin on bone.
Methods
Animals
72 eleven-week-old virgin female Swiss-Webster mice
were purchased from Taconic Farms (Germantown, NY)
and maintained at the animal research facility at the Beth
Israel Deaconess Medical Center. Animals were fed Purina
Formulab Diet containing 1% Ca (Formulab, Richmond,
IN) and water ad libitum throughout the experiment. Mice
were sacrificed by CO2 inhalation.
Experimental protocol
The experimental protocol was approved by the Institu-
tional Animal Care and Use Committee of the Beth Israel
Deaconess Medical Center. The study design is shown
schematically in Figure 1. The mice were randomly subdi-
vided into five groups of bilaterally ovariectomized (OVX)
and three groups of SHAM OVX animals, with 9 animals
in each group. A group of each of OVX and SHAM animals
was sacrificed one week postoperatively (T1/OVX and T1/
SHAM, respectively) and served as baseline controls. Four
additional weeks were allowed to pass before initiation of
treatment in the remaining groups in order to permit sig-
nificant bone loss to occur in the OVX animals. At this
time, one group of OVX (T5/OVX) and one group of sham
OVX mice (T5/SHAM) were sacrificed to evaluate pre-
treatment bone loss.
An eight-week daily treatment (5 days a week) consisting
of daily gavage of either 10 mg/kg of simvastatin (Apin
Chemical Limited UK, Oxfordshire, England) or vehicle
(VEH) only (0.5% methylcellulose in H2O) was adminis-
tered to the T13/OVX/SVS and T13/OVX/VEH groups,
respectively.
An additional control group of OVX mice received daily
treatment (5 days a week) consisting of subcutaneous (sc)
injections of 80 µg/kg per day of hPTH (1–34) (Advanced
ChemTech, Louisville, KY, USA). All groups were sacri-
ficed after completion of the 13 week study.
Micro-computed tomography analysis
For a detailed qualitative and quantitative 3-D evaluation,
whole femoral bones were examined by a desktop µCT
system (µCT 20, Scanco Medical AG, Bassersdorf, Switzer-
land) equipped with a 10 µm focal spot microfocus X-ray
tube as a source [12]. For image acquisition, the specimen
was mounted on a turntable shifted automatically in an
axial direction over 216° (180° plus half fan angle on ei-
ther side), taking 600 projections. To scan the entire fem-
oral width (3.4–5.1 mm), including the femoral head, a
total of 100–150 micro-tomographic slices were acquired
at a 34 µm slice increment. CT images were reconstructed
in 512 × 512 pixel matrices using a standard convolution-
backprojection procedure with a Shepp and Logan filter.
Images were stored in 3-D arrays with an isotropic voxel
size of 34 µm. A constrained 3-D Gaussian filter was used
to partly suppress the noise in the volumes and the min-
eralized tissue was segmented from soft tissues by a global
thresholding procedure [13]. Morphometric parameters
were determined using a direct 3-D approach [14] in three
different pre-selected analysis regions: whole bone (in-
cluding the articular ends), secondary spongiosa in the
distal metaphysis, and diaphyseal cortical bone. Parame-
ters determined in the metaphyseal trabecular bone in-
cluded bone volume density (BV/TV), bone surface
density (BS/TV), trabecular number (Tb.N), trabecular
thickness (Tb.Th), trabecular spacing (Tb.Sp) and connec-
tivity density. Cortical volume (TV), percent marrowBMC Musculoskeletal Disorders 2003, 4 http://www.biomedcentral.com/1471-2474/4/8
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volume (%MV) and cortical thickness (Ct.Th) were as-
sessed in a 1 mm-thick slab in the mid-diaphysis.
Mass Spectrometry
Bond Elut C8 SPE cartridges (1 ml/100 mg) were pur-
chased from Varian/Sample Preparation Products (Har-
bor City, CA, USA). ESI-MS (electrospray ionization mass
spectrometry) were recorded on a Micromass Platform
LCZ system equipped with an electrospray ionization
source and a Waters 2690 Separation Module. For analyt-
ical RP-HPLC (Reverse-phase high performance liquid
chromatography Vydac C18 columns were used; the sol-
vent system used included Water/TFA (1000:1, eluent A)
and Acetonitrile/TFA (1000:1, eluent B). Linear elution-
gradient was used ("Waters Gradient 6", t = 0 min, 10% B;
t = 1 min, 45% B; t = 21 min, 60% B; t = 26 100% MeOH;
t = 35 min, 10% B). Flow rates were 0.2 ml/min and the
detection wavelengths were set to 220 and 240 nm.
Sample preparation
All sample preparation procedures were carried out in an
ice-water bath. Stock solution of simvastatin was prepared
in ethanol and of simvastatin hydroxy acid in methanol-
water (90:10) at 4°C. Calibration standards were pre-
pared fresh for each analysis, by dilutions in methanol-
water (70:30). The doses of the standards at the respective
points on the calibration graphs were 1, 10, 30, 60, 100,
150 ng. Recovery of simvastatin and of simavastatin hy-
droxy acid from mouse plasma following the extraction
procedure below, was assessed by comparison of samples
at three doses (30, 80 and 150 ng), which were used to
spike 0.1 ml mouse plasma followed by extraction and in-
jection into LC-MS, to similar doses directly injected to
the LC-MS. The quantitation was based on integration of
the area under the respective peaks in the UV spectra ob-
tained at 240 nm (approximately the λmax for both simv-
astatin and simavastatin hydroxy acid). Each of the
samples from the in vivo tests (0.15 ml), or the recovery
test above, was diluted with 0.4 ml of water prior to
extraction.
Extraction procedure
This procedure was based on the previously published
protocol by Wu et al. [15], implementing minor modifi-
cations. Each solid-phase extraction cartridge (1 ml/100
mg) was conditioned with Methanol-water (50:50). The
diluted sample (see Sample preparation) was loaded on
to each cartridge, followed by low vacuum (1 min), and
each cartridge was subsequently washed with 1 ml H2O, 1
ml 5% formic acid, 1 ml H2O and dried for 1 min. Each
cartridge was then eluted with 1 ml of methanol-water
(70:30) solution and with 1 ml of acetonitrile, followed
by low vacuum (1 min). The combined eluates were evap-
orated to dryness in a SpeedVac at 45°C. The dry residues
were reconstituted in 100 µl of ammonium acetate (10
mm, pH 4.0)-acetonitrile (30:70). The reconstituted ex-
tracts were transferred into autosampler vials and 50 µl of
each sample were injected on to the LC column (equiva-
lent to 75 µl of plasma sample).
Figure 1
Schematic representation of the experimental design
T0 T1 T2 T3 T4 T5 T6
No treatment
Daily s.c. PTH (80 µg/Kg) or
gavage SVS (10 mg/Kg) or gavage vehicle
T1/SHAM T1/OVX T5/SHAM
OVX Sacrifice
T5/OVX
Sacrifice
T13/SHAM T13/OVX/VEH
T13/OVX/PTH T13/OVX/SVS
T13
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Osteocalcin assay
Blood was sampled prior to sacrifice to determine serum
levels of osteocalcin (OC). Serum intact OC was measured
by a two-site immunoradiometric assay (IRMA kit,
Immutopics Inc., San Clemente, CA) against the mid-re-
gion C-terminal and amino-terminal position of mouse
OC with a known sensitivity of 0.1 ng/mL. Intra- and in-
terassay CVs were 2.3% and 4.4%, respectively.
Statistical Analysis
A power analysis was conducted in planning the experi-
ments to determine the sufficient number of mouse fe-
murs in this investigation. A total sample size of 72
animals (n = 9 per treatment condition) was required to
provide 90% power (α = 0.05, β = 0.1) to detect a signifi-
cant difference of 1 standard deviation (effect size = 1.0)
between the Simvastatin, PTH, OVX, and SHAM treat-
ments with respect to each trabecular and cortical bone
parameter using one-way analysis of variance (ANOVA)
with a two-tailed significance level of 0.05. Sample size
calculations were determined using the nQuery Advisor
software program (version 4.0, Statistical Solutions, Bos-
ton, MA).
All continuous variables were checked for normality using
the Kolmogorov-Smirnov goodness-of-fit test and were
found to follow a normal distribution closely [16]. There-
fore, results are reported in terms of means ± standard de-
viation (SD). Treatment groups were compared with
respect to trabecular and cortical bone parameters ob-
tained by µCT by use of analysis of variance (ANOVA)
with the Fisher least significant difference (LSD) method
for post-hoc multiple testing [17]. A two-tailed value of p <
0.05 was established as the criterion for statistical signifi-
cance. Statistical analysis was performed using the SPSS
(version 11.0, SPSS Inc., Chicago, IL) and SAS (version
6.12, SAS Institute, Cary, NC) software packages.
Results
Effects of OVX on bone loss
Consistent with the findings in our recent study [11], µCT
analyses of femoral trabecular and cortical bone showed
little change over the duration of the study in any of the
structural variables for SHAM OVX Swiss-Webster mice
(groups T1/SHAM, T5/SHAM, T13/SHAM). OVX mice
demonstrated significantly lower trabecular bone volume
density (BV/TV) compared to SHAM controls at 1 week
(15 ± 6% vs. 26 ± 5%, P < 0.001) 5 weeks (5 ± 3% vs. 28
± 12%, P < 0.001), and showed a reduction of 85% at 13
weeks (5 ± 4% vs. 34 ± 11%, P < 0.001, Table 1). In addi-
tion, trabecular thickness, spacing and number were sig-
nificantly different in OVX mice compared to SHAM
controls at 5 and 13 weeks (all P < 0.001). However, cor-
tical parameters including total volume, marrow volume/
total volume, and thickness were not significantly differ-
ent between OVX and SHAM controls throughout the 13-
week study course (all P > 0.20, Table 1).
Effect of PTH and SVS treatment on bone
At 13 weeks, trabecular bone volume density (BV/TV) in
mice treated with PTH alone (T13/OVX/PTH) was 4.2-
fold higher than vehicle-treated animals (T13/OVX/VEH)
(Table 2). PTH treatment was associated with significant
increases in Tb.Th and Tb.N as well as an expected de-
crease in Tb.Sp. In addition, significant differences in cor-
tical %MV/TV and thickness were observed at 13 weeks (P
< 0.01, Table 2).
In comparison, trabecular BV/TV in SVS-treated animals at
13 weeks (T13/OVX/SVS) was not significantly increased
over that observed in vehicle-treated animals (T13/OVX/
Table 1: Control Data Throughout the Course of the Study
Parameter OVX T1 Sham T1 OVX T1 OVX T5 Sham T5 OVX T5 OVX T13 Sham T13 OVX T13
(n = 9) (n = 9) vs. Sham T1 (n = 9) (n = 9) vs. Sham T5 (n = 9) (n = 9) vs. Sham T13
Assessment at 1 Week p-value Assessment at 5 Weeks p-value Assessment at 13 Weeks p-value
Full BV/TV (%) 69 ± 3 72 ± 2 <0.001 67 ± 2 75 ± 3 <0.001 67 ± 3 75 ± 3 <0.001
Tb.BV/TV (%) 15 ± 6 26 ± 5 <0.001 5 ± 3 28 ± 12 <0.001 5 ± 4 34 ± 11 <0.001
Tb.Th (mm) 0.08 ± 0.01 0.1 ± 0.01 <0.001 0.06 ± 0.01 0.10 ± 0.01 <0.001 0.06 ± 0.01 0.11 ± 0.02 <0.001
Tb.Sp (mm) 0.28 ± 0.50 0.28 ± 0.05 NS 0.66 ± 0.16 0.28 ± 0.12 <0.001 0.62 ± 0.21 0.24 ± 0.61 <0.001
Tb.N (1/mm) 3.7 ± 0.6 3.7 ± 0.5 NS 1.6 ± 0.5 3.9 ± 0.9 <0.001 1.9 ± 0.9 4.2 ± 0.7 <0.001
Tb.Conn (1/mm3) 17 ± 11 28 ± 7 NS 4 ± 3 24 ± 8 <0.001 5 ± 4 27 ± 9 <0.001
Ct.TV (mm3) 1.9 ± 0.2 1.9 ± 0.3 NS 1.9 ± 0.2 1.9 ± 0.1 NS 1.9 ± 0.1 2.0 ± 0.2 NS
Ct.MV/TV (%) 56 ± 3 52 ± 3 0.02 50 ± 3 51 ± 3 NS 49 ± 3 47 ± 4 NS
Ct.Th (mm) 0.22 ± 0.02 0.25 ± 0.03 NS 0.26 ± 0.02 0.26 ± 0.02 NS 0.26 ± 0.02 0.29 ± 0.04 NS
Plus-minus values represent the mean ± standard deviation. Statistical analysis was performed by ANOVA with post-hoc multiple comparisons using 
the Fisher least significant difference (LSD) method. T1 = sacrificed after 1 week; T5 = sacrificed after 5 weeks; T13 = sacrificed after 13 weeks. 
Vehicle-treated animals. NS = not significant; Full BV/TV: Whole Bone Volume Density; Tb. BV/TV: Trabecular Bone Volume Density; Tb.Th: 
Trabecular Thickness; Tb.Sp: Trabecular Spacing; Tb.N: Trabecular Number; Ct.TV: Cortical Total Volume; Ct.MV/TV: Cortical Marrow Volume 
Density; Ct.Th: Cortical Thickness.BMC Musculoskeletal Disorders 2003, 4 http://www.biomedcentral.com/1471-2474/4/8
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VEH) (Figure 2). Furthermore, none of the other
trabecular bone parameters (Tb.Th, Tb.Sp and Tb.N) re-
vealed a significant difference after 13 weeks of SVS treat-
ment when compared to T13/OVX/VEH animals, (all P =
NS, Table 2).
Similarly, whole bone volume density at T13 was higher
in animals treated with PTH compared to the OVX group
(76 ± 4% vs. 67 ± 3%, p < 0.001), whereas SVS treatment
had no significant effect (68 ± 3% vs. 67 ± 3%, p = NS). In
addition, cortical thickness evaluated at T13 was higher in
the PTH treatment group compared to the OVX group
(0.31 ± 0.03 mm vs. 0.26 ± 0.02 mm, p < 0.001), whereas
SVS treatment exhibited no effect (0.27 ± 0.01 mm vs.
0.26 ± 0.02 mm, p = NS, Table 2).
Osteocalcin
Mean serum osteocalcin (OC) of SHAM and OVX treated
animals did not change significantly when compared at 1,
5 and 13 weeks. PTH treated mice, however revealed an
increase (596 ± 138 ng/ml) over T13/OVX/VEH animals
(252 ± 57 ng/ml, P < 0.001, Figure 2). SVS treatment at 13
weeks, however, caused no significant increases in OC
compared to T13/OVX/VEH animals (309 ± 74 ng/ml vs.
252 ± 57 ng/ml, p = NS, Figure 3).
Detection of the active Simvastatin hydroxy acid metabo-
lite in mouse serum after gavage administration
In this study, SVS was administered by gavage, and re-
quires hepatic conversion to the metabolically active β-hy-
droxy acid (SVS-OH). Because SVS failed to have any
effect on any static µCT parameter measured at either site
in mouse femur, we conducted separate experiments de-
signed to detect the presence of SVS-OH in mouse serum
after SVS gavage by liquid chromatography/mass spec-
trometry (LC/MS).
Reverse-phase high performance liquid chromatography
(RP-HPLC) tandem electrospray ionization mass spec-
trometry (ESI-MS) method published by Wu et al. [15]
was used to analyze samples of mouse serum for the pres-
ence of SVS and SVS-OH. The identity of the eluted peak
in RP-HPLC was established by the determination of the
mass associated with it by ESI-MS. The retention times for
SVS and SVS-OH were 19.5 ± 0.5 and 15.35 ± 0.20 min,
respectively. Threshold of detection on the LC-MS at λ240
nm (AUFS = 0.1), the most sensitive wavelength, for both
SVS and the SVS-OH was ~1 ng. Calibration curves for
both the SVS and the SVS-OH extracted from the area un-
der the curve in the HPLC profile was linear in the range
of 1–150 ng. These curves were used to quantitate the drug
and metabolite levels in mouse plasma. Based on the spik-
ing of mouse plasma ex-vivo with known amounts of drug
and subjecting the samples for the extraction procedure,
the efficiency of drugs recovery was estimated to be 60–
75% for SVS and 70–85% for SVS-OH. Figure 4 is a repre-
sentative example of the LC-MS analysis of a sample col-
lected from a mouse 30 min after treatment with 100 mg/
kg SVS. In this sample both the RP-HPLC tracing and the
ESI-MS analysis of the peaks corresponding to the drug
and its metabolite confirm the presence of both in the
serum.
Both residual SVS and its in situ-generated metabolite SVS-
OH were detected in the mouse plasma as early as 10 min
after gavage administration of 100 mg/kg of SVS (the
shortest sampling interval). The levels of SVS and SVS-OH
in the plasma 10 min after administration were 97.3 and
15.3 ng/µl, respectively. These findings establish the bioa-
vailability of the drug following this route of
administration.
Discussion
The aim of this study was to investigate the effect of Sim-
vastatin on bone in an established mouse model of oste-
Table 2: Effects of Simvastatin and PTH on Mouse Femurs at 13 weeks as Determined by µCT*
Parameter OVX T13 (n = 9) PTH T13 (n = 9) SVS T13 (n = 9) OVX vs. PTH p-value SVS vs. OVX p-value PTH vs. SVS p-value
Full BV/TV (%) 67 ± 3 76 ± 4 68 ± 2 <0.001 NS <0.001
Tb.BV/TV (%) 5 ± 4 21 ± 11 5 ± 4 <0.001 NS <0.001
Tb.Th (mm) 0.06 ± 0.01 0.09 ± 0.01 0.06 ± 0.01 <0.001 NS <0.001
Tb.Sp (mm) 0.62 ± 0.21 0.40 ± 0.24 0.66 ± 0.20 <0.05 NS 0.03
Tb.N (1/mm) 1.9 ± 0.9 3.1 ± 1.2 1.7 ± 0.7 0.02 NS <0.01
Tb.Conn (1/mm3) 5 ± 4 17 ± 10 3 ± 3 <0.01 NS <0.001
Ct.TV (mm3) 1.9 ± 0.1 2.0 ± 0.2 1.9 ± 0.1 NS NS NS
Ct.MV/TV (%) 49 ± 3 43 ± 6 49 ± 2 <0.01 NS <0.01
Ct.Th (mm) 0.26 ± 0.02 0.31 ± 0.03 0.27 ± 0.01 <0.001 NS <0.001
* Data are presented as means ± standard deviation. Groups were compared by ANOVA with post-hoc Fisher least significant difference (LSD) 
method. All p-values are two-tailed. NS = not significant.BMC Musculoskeletal Disorders 2003, 4 http://www.biomedcentral.com/1471-2474/4/8
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oporosis. This Swiss-Webster outbred mouse strain
utilized in this study has proven to be a valuable model
for investigating the efficacy of both anabolic and anti-re-
sorptive therapies for the treatment of osteoporosis. Here,
we have used PTH as a positive control [11], and com-
pared its effects to SVS. While PTH demonstrated the ex-
pected anabolic effect on bone, SVS failed to stimulate
bone formation, despite our verification by LC/MS of the
active SVS-OH metabolite in mouse serum.
The SVS-OH metabolite is first detectable in mouse serum
by 10 minutes after gavage administration, and serum lev-
els of SVS-OH continued to be observed by both mass-
spectrometric and UV measurements through the last
serum samples collected at 50 minutes post-gavage. Other
experiments failed to detect SVS-OH at longer post-gavage
timepoints of 3 and 24 hours. These data are in general
agreement with studies in both rats and canines that
calculate peak serum levels of SVS-OH at 40–60 minutes
after gavage administration [18]. Thus, although we failed
to document any bone anabolic activity of SVS in a mouse
model of OVX-induced osteoporosis, LC/MS analysis of
the SVS-OH metabolite in mouse serum document the ef-
ficacy of our gavage administration of SVS to experimental
mice.
Extrapolating from mice to humans, the dose of SVS ad-
ministered in this study was approximately 400-fold high-
er than the average dose given to humans. The results
suggest that Simvastatin does not enhance bone forma-
tion in this mouse model in vivo, despite our ability to
verify the presence of the SVS-OH metabolite in mouse se-
rum by LC/MS analysis. Furthermore, the osteocalcin as-
Figure 2
3D µCT images of distal femoral metaphyseal trabecular bone of 13 week SHAM, OVX-VEH-treated, OVX PTH treated, OVX 
SVS treated Swiss-Webster mice. Images were obtained from animals with median cancellous BV/TV values.
Sham
Vehicle
T13
Ovariectomized
Vehicle PTH SVS
T13 T13 T13
Trabecular BV/TV (%)
34 ± ± ± ± 11 5 ± ± ± ± 4 5 ± ± ± ± 4 21 ± ± ± ± 11BMC Musculoskeletal Disorders 2003, 4 http://www.biomedcentral.com/1471-2474/4/8
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say did not suggest any increase in osteoblast activity in
SVS treated mice, consistent with its failure to increase
bone density.
It is generally accepted that the hydroxy acid form of stat-
ins are potent inhibitors of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, an enzyme that plays
a critical role in cholesterol metabolism, where they block
substrate accessibility to HMG-CoA reductase, effectively
subverting cholesterol levels of HDL [19–21]. In addition
to lowering cholesterol, statins seem to have a number of
additional effects, such as the nitric oxide-mediated pro-
motion of new blood vessel growth [22], protection
against oxidative modification of low-density lipoprotein,
as well as anti-inflammatory effects and a reduction in C-
reactive protein levels [23]. All statins limit cholesterol bi-
osynthesis by inhibiting the committed step in the bio-
synthesis of isoprenoids and sterols [24].
Considering the enormous potential impact of statins on
the treatment of osteoporosis, several groups have further
investigated the skeletal effects of statin use. Several
groups have failed to confirm the initially reported ana-
bolic effect of systemically administered statins in vivo in
rats [25–27]. One obvious criticism of the negative data in
these studies is that they did not verify the actual presence
of statin in the animal serum. This limitation may be of
importance, as Crawford et al [27] could detect an in-
crease in cortical bone when statin was administered lo-
cally. Our study demonstrated the presence of
systemically administered the SVS-OH metabolite in the
mouse serum by LC/MS analysis.
Figure 3
Mean Serum Osteocalcin levels at 13 weeks. While PTH treatment (596 ± 138 ng/ml) was significantly different (P < 0.001,*) 
from OVX (252 ± 57 ng/ml) and SVS (309 ± 74 ng/ml), SVS treatment was not significantly different (NS) from OVX vehicle 
treated animals after 13 weeks.
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The exact mechanism by which statins perform their ef-
fects on bone cell function is a central issue. It has been
hypothesized that statins mediate their effects by increas-
ing the expression in bone of the growth factor bone mor-
phogenic protein-2 (BMP-2) which in turn leads to
osteoblast differentiation and bone formation [2]. This
mechanism of action has been addressed by Baumann et
al. in rats, where the anabolic effect of lovastatin on bone
was at least partially due to their inhibiting effect on oste-
oclast development[28]. Similarly, in the mouse calvaria
model Gasser et al. failed to detect any anabolic activity of
statins in bone and suggested that the disruption of the
capillary integrity and local bleeding might explain some
of the previously reported bone responses [26].
Several studies in humans reported a decreased risk of
fracture after statin treatment [3,29,30]. However larger
human studies failed to confirm statins beneficial effect
on bone. LaCroix et al. found the risk of hip and arm frac-
ture to be similar among women who used statins and
those who did not take lipid lowering medication [31].
Van Staa et al. examining 218,062 individuals with a frac-
ture in the General Practice Database in the United King-
dom, and found no relationship between statin use and
nonspine fracture [32]. Interestingly, a report by Meier [3]
had used the exact same database as van Staa et al. [32],
but sampled a much larger cohort (218,062 individuals
with fracture) than Meier (3940), and in addition, select-
ed an age and gender matched control patient for every
fracture patient. The clinical data available at the moment
does not allow the conclusion that statin treatment has a
postive relationship with fracture risk.
Figure 4
Liquid chromatography/mass spectrometry (LC/MS) for SVS (M + Na+ = 442 kD) and SVS-OH (M + Na+ = 460 kD) of mouse 
serum 30 min after gavage with 100 mg/kg SVS.
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Similarly as described in the clinical trials, the early ani-
mal studies reported data supportive of the initial findings
[1,4–6,33,34]. These results however, were not substanti-
ated in later studies in rodents, where SVS had no or little
effect on bone mineral density [26]. However, none of the
studies has verified the actual presence of the active SVS-
OH metabolite in the animal serum, as shown in this
study. In combination with the osteocalcin data, this re-
port provides strong evidence that simvastatin does not
have an effect on bone in an established Swiss Webster
mouse model of OVX-induced osteoporosis.
Conclusion
In summary, the currently available data on the effects of
statins on bone has done little to confirm the finding that
statin therapy increases bone mass and thereby lowers
fracture risk. Few of the studies in animals and humans
have been able to show a predictable beneficial effect on
bone mass and bone turnover. This report verifies the
presence of the active SVS-OH metabolite in the mouse se-
rum yet failed to demonstrate any beneficial effect on
bone. While statins have clear effects on bone formation
in vitro, the formulation of existing 'liver-targeted' statins
may require further refinement for efficacy on bone for-
mation in vivo.
Competing interests
None declared.
Authors contributions
D. von Stechow: participated in the study coordination,
perfomed the microCT analysis and drafted the
manuscript
S. Fish: carried out the animal experiments
D. Yahalom: carried out the mass spec analsysis
I. Bab: participated in the design of the study
M. Chorev: participated in the mass spec analysis
R. Müller: participated in the microCT analysis
J. M. Alexander: conceived of the study, and participated
in its design and coordination, and edited the manuscript
Acknowledgements
This work was supported in part by a grant from the William F Milton Fund 
at Harvard Medical School.
References
1. Banu J and Kalu DN Effects of cerivastatin and parathyroid hor-
mone on the lumbar vertebra of aging male Sprague-Dawley
rats Bone 2002, 31:173-179
2. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B,
Zhao M and Gutierrez G Stimulation of bone formation in vitro
and in rodents by statins Science 1999, 286:1946-1949
3. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B and Jick H HMG-
CoA reductase inhibitors and the risk of fractures Jama 2000,
283:3205-3210
4. Oxlund H, Dalstra M and Andreassen TT Statin given perorally to
adult rats increases cancellous bone mass and compressive
strength Calcif Tissue Int 2001, 69:299-304
5. Skoglund B, Forslund C and Aspenberg P Simvastatin improves
fracture healing in mice J Bone Miner Res 2002, 17:2004-2008
6. Whang K, Zhao M, Qaio M, Rossini G, Horn D, Garrett IR, Mundy
GR and Chen D Administration of lovastatin locally in low dos-
es in a novel; delivery system induces prolonged bone
formation J Bone Miner Res 2000, 15(Suppl):S225
7. Cummings SR and Bauer DC Do statins prevent both cardiovas-
cular disease and fracture? Jama 2000, 283:3255-3257
8. Schneider EL and Guralnik JM The aging of America. Impact on
health care costs Jama 1990, 263:2335-2340
9. Looker AC, Johnston CC Jr, Wahner HW, Dunn WL, Calvo MS, Har-
ris TB, Heyse SP and Lindsay RL Prevalence of low femoral bone
density in older U.S. women from NHANES III J Bone Miner Res
1995, 10:796-802
10. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster
JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O and
Mitlak BH Effect of parathyroid hormone (1–34) on fractures
and bone mineral density in postmenopausal women with
osteoporosis N Engl J Med 2001, 344:1434-1441
11. Alexander JM, Bab I, Fish S, Müller R, Uchiyama T, Gronowicz G, Na-
hounou M, Zhao Q, White DW, Chorev M, Gazit D and Rosenblatt
M Human parathyroid hormone 1–34 reverses bone loss in
ovariectomized mice J Bone Miner Res 2001, 16:1665-1673
12. Rüegsegger P, Koller B and Müller R A microtomographic system
for the nondestructive evaluation of bone architecture Calcif
Tissue Int 1996, 58:24-29
13. Müller R and Rüegsegger P Micro-tomographic imaging for the
nondestructive evaluation of trabecular bone architecture
Stud Health Technol Inform 1997, 40:61-79
14. Hildebrand T, Laib A, Müller R, Dequeker J and Rüegsegger P Direct
three-dimensional morphometric analysis of human cancel-
lous bone: microstructural data from spine, femur, iliac
crest, and calcaneus J Bone Miner Res 1999, 14:1167-1174
15. Wu Y, Zhao J, Henion J, Korfmacher WA, Lapiguera AP and Lin CC
Microsample determination of lovastatin and its hydroxy
acid metabolite in mouse and rat plasma by liquid chroma-
tography/ionspray tandem mass spectrometry J Mass Spectrom
1997, 32:379-387
16. Conover WJ Practical nonparametric statistics  New York: John Wiley
1999, 
17. Armitage P and Berry G Statistical methods in medical research Cam-
bridge, MA: Blackwell Science 1994, 
18. Vickers S, Duncan CA, Chen IW, Rosegay A and Duggan DE Meta-
bolic disposition studies on simvastatin, a cholesterol-lower-
ing prodrug Drug Metabolism and Disposition 1990, 18:138-145
19. Istvan ES and Deisenhofer J Structural mechanism for statin in-
hibition of HMG-CoA reductase Science 2001, 292:1160-1164
20. Altieri DC Statins' benefits begin to sprout J Clin Invest 2001,
108:365-366
21. Rao S, Porter DC, Chen X, Herliczek T, Lowe M and Keyomarsi K
Lovastatin-mediated G1 arrest is through inhibition of the
proteasome, independent of hydroxymethyl glutaryl-CoA
reductase Proc Natl Acad Sci U S A 1999, 96:7797-7802
22. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC
and Walsh K The HMG-CoA reductase inhibitor simvastatin
activates the protein kinase Akt and promotes angiogenesis
in normocholesterolemic animals Nat Med 2000, 6:1004-1010
23. Davignon J and Laaksonen R Low-density lipoprotein-independ-
ent effects of statins Curr Opin Lipidol 1999, 10:543-559
24. Corsini A, Maggi FM and Catapano AL Pharmacology of compet-
itive inhibitors of HMG-CoA reductase  Pharmacol Res 1995,
31:9-27
25. Yao W, Li CY, Farmer RW, Chen JL, Mo A, Cooper R, Chmielewski
P, Setterberg RB, Jee WSS and Lundy MW Simvastatin did not
prevent bone loss in ovariectomized rats J Bone Miner Res 2001,
16:S294Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Musculoskeletal Disorders 2003, 4 http://www.biomedcentral.com/1471-2474/4/8
Page 10 of 10
(page number not for citation purposes)
26. Gasser JA Fluvastatin and cervastatin are not anabolic for
bone after local and systemic administration of non-toxic
doses in mice and rats J Bone Miner Res 2001, 16:S295
27. Crawford DT, Qi H, Chidesy-Frink KL, Thompson DD and Ke HZ
Statin increases cortical bone in young male rats by single,
local administration but fails to restore bone in
ovariectomized (OVX) rats by daily systemic administration
J Bone Miner Res 2001, 16:S295
28. Baumann AP, Grasser W, Petras S, Harwood HJ, Thompson DD and
Paralkar V Inhibition of osteoclast formation by statins J Bone
Miner Res 2001, 16:S507
29. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG,
Goodman MJ, Gurwitz JH, LaCroix AZ and Platt R Inhibitors of hy-
droxymethylglutaryl-coenzyme A reductase and risk of frac-
ture among older women Lancet 2000, 355:2185-2188
30. Wang PS, Solomon DH, Mogun H and Avorn J HMG-CoA reduct-
ase inhibitors and the risk of hip fractures in elderly patients
Jama 2000, 283:3211-3216
31. LaCroix AZ, Cauley JA, Jackson R, McGowan J, Pettinger M, Hsia J,
Chen Z, Lewis C, Bauer DC, Daugherty S, McNeeley SG and Passaro
M Does statin use reduce the risk of fracture in postmeno-
pausal women? Results from the Women's Health Initiative
Observational Study (WHIOS) J Bone Miner Res 2000, 15(Sup-
pl):S155
32. van Staa TP, Wegman SLJ, F. dV, Leufkens HGM and Cooper C Use
of Statins and risk of fracture J Bone Miner Res 2000, 16(Sup-
pl):S155
33. Oxlund H Simvastatin given perorally increases the cortical
bone formation rate in adult rats J Bone Miner Res 1999, 15(Sup-
pl):S313
34. Garrett IR, Esparza J, Chen D, Zhao M, Guiterrez G, Escobedo A,
Horn D and Mundy GR Statins mediate their effects on osteob-
lasts by inhibition of HMG-CoA reductase and ultimately
BMP-2 J Bone Miner Res 2000, 15(Suppl):
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2474/4/8/prepub